Pemetrexed in gastric cancer.

Alberto F. Sobrero(Ospedale Policlinico San Martino), Franco Decian(Alleanza Contro il Cancro), Danila Comandini(Ospedale Policlinico San Martino), Francesco Caprioni(Ospedale Policlinico San Martino), Giuseppe Fornarini(Ospedale Policlinico San Martino), Serafina Mammoliti(Ospedale Policlinico San Martino), Stefano Baldo(University of Genoa)

PubMed

November 1, 2004

Cited by 3

Related Papers

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|333

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

|The Lancet. Gastroenterology & hepatology|2020|249

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

|Clinical Cancer Research|2019|240

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

|The Lancet Oncology|2021|148

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

|The Oncologist|2018|144